Wednesday, December 27, 2017 10:15 PM ET
Continued Level of Significant Insider Selling at CymaBay Therapeutics (CBAY)
A notable insider sale of the shares of CymaBay Therapeutics was revealed in a form 4 document filed with the SEC today, showing — Kurt von Emster, Director — disposed of 173,192 shares in the company having a market value of approximately $1,629,304. There have been 2 insiders with buy/sell transactions in the past 90 days prior to this filing. These trades have resulted in the purchase of 5,000 company shares and the sale of 433,577 company shares over this time period. Adding the most recent activity to this 90-day history indicates insider trades have been net sales of 601,769 shares and have averaged 203,923 shares per transaction over this time period.
The number of insider buy/sell trades at CymaBay Therapeutics is greater than that of the 279 peer company average over the last 90-day period. The Bio Therapeutic Drugs peer group saw 313 buy/sell trades during this period for an average of 1.1 transactions per company. However, the number of shares traded per transaction by CymaBay Therapeutics insiders is lower than its peers. Within the peer group there were 43,516,766 shares purchased and 36,594,669 shares sold with company insiders purchasing 33,766 shares on average over this time period.
The data used in creating and writing in this story eliminates all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers.
Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at firstname.lastname@example.org. Copyright 2017 UpTick Data Technologies. All rights reserved.